Tuesday, 29 October 2013

Key Safety Questions May Linger for FDA-Expedited Drugs

MONDAY, Oct. 28 (HealthDay News) -- When the U.S. Food and Drug Administration whisks new drugs to market, they do get to patients faster. But they are often not tested as strictly as treatments that get standard reviews, a new study shows. The re...

Source: http://health.yahoo.net/news/s/hsn/key-safety-questions-may-linger-for-fda-expedited-drugs

as example as an example explained here as explained here

No comments:

Post a Comment

Note: only a member of this blog may post a comment.